Bioventus Lowers 2026 Revenue Outlook to $590 Million-$595 Million

The company reaffirmed adjusted EPS guidance of $0.75 to $0.79 and expects mid-single-digit revenue growth in the fourth quarter.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.